2 Biotechs That Could Get Bought Out in 2024

Although most pharma companies spend billions on developing drugs to replace aging stars, mergers and acquisitions (M&A) serve as another important tool drug developers frequently use to restock the cupboard, so to speak.

For investors, M&A can provide a quick, and often hefty, profit windfall. In only the last few weeks, several deals have been announced at premiums ranging from 22% to 104% relative to the acquired company's pre-deal closing price. Armed with this background, here is a look at two biopharma companies that could be on big pharma's radar in 2024.